United States Orthobiologics Market Report 2021: Bone Graft Substitutes, Cellular Allografts, Orthopedic Cell Therapy, Hyaluronic Acid Viscosupplementation & Orthopedic Cartilage Repair Devices - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "U.S. Orthobiologics Market Analysis - COVID19 - 2019-2025 - MedSuite - Includes: Bone Graft Substitutes, Cellular Allografts, Growth Factors, Orthopedic Cell Therapy, Hyaluronic Acid Viscosupplementation & Orthopedic Cartilage Repair Devices" report has been added to ResearchAndMarkets.com's offering.

U.S. orthopedic biomaterials market was valued at $3.1 billion in 2020. This is expected to increase over the forecast period to reach over $5 billion in 2025.

Throughout this medical market research, the publisher analyzed 47+ Orthobiologics companies in the United States and utilized their comprehensive methodology to understand the Market Sizes, Unit Sales, ASPs, Company Market Shares, and to create accurate forecasts.

While this report suite report contains all of the U.S. Orthobiologics market analysis, each of the market segments is also available as a stand-alone a report, MedCore.

U.S. Orthobiologics Market Insights

A particular trend in the U.S. orthopedic biomaterials market is competitors that are seeking to penetrate high-growth segments outside their traditional space by distributing existing products manufactured by other companies, rather than creating their own.

This often involves partnering with a company by taking on the costs associated with regulation and market approval, in exchange for exclusive market rights. The distributor then pays the manufacturer in royalties. The goal is to penetrate the high-growth segments and build or strengthen networks before the segment matures. This is especially the case for competitors in segments that are in decline, such as competitors in the five-injection hyaluronic acid treatment.

Medtronic leads the U.S. orthopedic biomaterials market. They have the largest share in the bone graft substitute segment and had their dominating product, INFUSET in the growth factor market.

This company's growth has been recovering since the negative media attention and lawsuits regarding off-label usage of its growth factor bone morphogenetic protein (BMP) product, INFUSE, which accounts for a significant portion of the company's revenue in biologic therapy.

Companies Mentioned

• AlloSource
• Alphatec Spine
• Anika Therapeutics
• Arteriocyte/Isto
• Arthrex
• Aziyo
• Baxter
• Berkely Advanced Biomaterials
• Biocomposites
• Bioventus
• Celling Biosciences
• Cerapedics
• Cesca Therapeutics
• Collagen Matrix
• Community Tissue Services
• Curasan
• DCI Donor Servicers
• DePuy Synthes
• Etex
• Exactech
• Ferring Pharmaceuticals
• Fidia Pharmaceuticals
• Globus Medical
• Harvest Technologies
• Integra LifeSciences
• Isto
• K2M
• LifeNet Health
• Medtronic
• Musculoskeletal Transplant Foundation (MTF)
• NuTech Spine/LifeLink Tissue Bank
• Novabone
• NuVasive
• Orthofix
• OrthogenRX
• Osiris Therapeutics
• Osteomed
• OStetic
• RTI Surgical
• Sanofi
• SeaSpine
• Spinal Elements
• Stryker
• Vericel
• Vivex
• Wright Medical
• Xtant
• Zimmer Biomet

For more information about this report visit https://www.researchandmarkets.com/r/f9yaw